CA2623554C - Methods and therapies for treating inflammatory conditions with exposed collagen - Google Patents
Methods and therapies for treating inflammatory conditions with exposed collagen Download PDFInfo
- Publication number
- CA2623554C CA2623554C CA2623554A CA2623554A CA2623554C CA 2623554 C CA2623554 C CA 2623554C CA 2623554 A CA2623554 A CA 2623554A CA 2623554 A CA2623554 A CA 2623554A CA 2623554 C CA2623554 C CA 2623554C
- Authority
- CA
- Canada
- Prior art keywords
- collagen
- substance
- composition
- antibody
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract description 22
- 102000008186 Collagen Human genes 0.000 title abstract description 12
- 108010035532 Collagen Proteins 0.000 title abstract description 12
- 229920001436 collagen Polymers 0.000 title abstract description 12
- 230000004968 inflammatory condition Effects 0.000 title abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 title description 3
- 239000000126 substance Substances 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 230000027455 binding Effects 0.000 claims abstract description 25
- 210000005166 vasculature Anatomy 0.000 claims abstract description 11
- 102000012422 Collagen Type I Human genes 0.000 claims description 21
- 108010022452 Collagen Type I Proteins 0.000 claims description 21
- 102000001187 Collagen Type III Human genes 0.000 claims description 21
- 108010069502 Collagen Type III Proteins 0.000 claims description 21
- 239000002738 chelating agent Substances 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 230000001588 bifunctional effect Effects 0.000 claims description 10
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- RAZLJUXJEOEYAM-UHFFFAOYSA-N 2-[bis[2-(2,6-dioxomorpholin-4-yl)ethyl]azaniumyl]acetate Chemical compound C1C(=O)OC(=O)CN1CCN(CC(=O)O)CCN1CC(=O)OC(=O)C1 RAZLJUXJEOEYAM-UHFFFAOYSA-N 0.000 claims description 6
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- -1 isothiocyanato cyclohexyl EDTA Chemical compound 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 2
- 238000003384 imaging method Methods 0.000 abstract description 15
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 20
- 230000003902 lesion Effects 0.000 description 15
- 238000011282 treatment Methods 0.000 description 11
- 241000283707 Capra Species 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- KJZYNXUDTRRSPN-OUBTZVSYSA-N holmium-166 Chemical compound [166Ho] KJZYNXUDTRRSPN-OUBTZVSYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 238000005773 Enders reaction Methods 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 238000001307 laser spectroscopy Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- ATJFFYVFTNAWJD-OIOBTWANSA-N tin-116 atom Chemical compound [116Sn] ATJFFYVFTNAWJD-OIOBTWANSA-N 0.000 description 1
- ATJFFYVFTNAWJD-YPZZEJLDSA-N tin-117 atom Chemical compound [117Sn] ATJFFYVFTNAWJD-YPZZEJLDSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72078805P | 2005-09-26 | 2005-09-26 | |
| US60/720,788 | 2005-09-26 | ||
| PCT/US2006/037764 WO2007038641A2 (en) | 2005-09-26 | 2006-09-26 | Methods and therapies for treating inflammatory conditions with exposed collagen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2623554A1 CA2623554A1 (en) | 2007-04-05 |
| CA2623554C true CA2623554C (en) | 2014-02-11 |
Family
ID=37900444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2623554A Expired - Fee Related CA2623554C (en) | 2005-09-26 | 2006-09-26 | Methods and therapies for treating inflammatory conditions with exposed collagen |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9623129B2 (enExample) |
| EP (1) | EP2341945A2 (enExample) |
| JP (1) | JP2009513568A (enExample) |
| CA (1) | CA2623554C (enExample) |
| WO (1) | WO2007038641A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114264B2 (en) * | 2005-02-10 | 2012-02-14 | Brookhaven Science Associates | Method of electroplating a conversion electron emitting source on implant |
| US8834338B2 (en) * | 2005-02-10 | 2014-09-16 | Snip Holdings, Inc. | Dosimetry implant for treating restenosis and hyperplasia |
| US8257681B2 (en) | 2008-12-26 | 2012-09-04 | Clear Vascular Inc. | Compositions of high specific activity SN-117M and methods of preparing the same |
| US10772931B2 (en) | 2014-04-25 | 2020-09-15 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
| NZ771201A (en) | 2017-04-06 | 2025-01-31 | Sustain Holdings Llc | Collagen Peptide-Based Medicament Compositions And Devices And Methods Of Production And Use Thereof |
| WO2019169241A1 (en) * | 2018-03-02 | 2019-09-06 | Serene, Llc | Methods of treating and imaging ungulate laminitis |
| PT3958889T (pt) | 2019-04-22 | 2025-04-10 | Sustain Holdings Llc | Composições de péptidos miméticos de colagénio para o tratamento de uma doença ou perturbação ocular so segmento posterior que envolve a retina, os vasos sanguíneos da retina, os nervos retinianos ou o nervo ótico |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647445A (en) | 1984-03-28 | 1987-03-03 | Massachusetts Institute Of Technology | Radiolabelled lipoproteins and method for making same |
| US4937067A (en) | 1984-12-13 | 1990-06-26 | Massachusetts Institute Of Technology | Method and means for detection of adrenal metabolic activity |
| US4660563A (en) | 1984-12-31 | 1987-04-28 | Massachusetts Institute Of Technology | Method and means for detection of arterial lesions |
| US5225181A (en) | 1985-06-07 | 1993-07-06 | The Research Foundation Of State University Of New York | Radiolabeled antiplatelet monoclonal antibody for imaging in-vivo thrombi |
| US4877599A (en) | 1986-11-10 | 1989-10-31 | New England Deaconess Hospital Corporation | Detection of vascular disease with labelled antibodies |
| US5726153A (en) * | 1988-05-02 | 1998-03-10 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
| AU628357B2 (en) | 1988-05-02 | 1992-09-17 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
| CA1340977C (en) | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
| US5334729A (en) | 1989-06-29 | 1994-08-02 | Associated Universities, Inc. | Stable radiometal antibody immunoconjugates |
| US7238340B1 (en) * | 1991-11-27 | 2007-07-03 | Cis Bio International | Monoamine, diamide, thiol-containing metal chelating agents |
| ATE237365T1 (de) | 1992-03-13 | 2003-05-15 | Diatide Inc | Technetium-99-markierte peptide zur visualisierung vom entzuendungen |
| US5292938A (en) | 1992-04-13 | 1994-03-08 | Associated Universities, Inc. | Synthesis of 4-substituted-trans-1, 2-diaminocyclohexyl polyaminocarboxylate metal chelating agents for the preparation of stable radiometal antibody immunoconjugates for therapy and spect and pet imaging |
| US5429133A (en) | 1992-12-18 | 1995-07-04 | Neoprobe Corporation | Radiation responsive laparoscopic instrument |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| US5968477A (en) | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| US5783169A (en) | 1995-07-26 | 1998-07-21 | Brookhaven Science Associates Llc | Rigid bifunctional chelating agents |
| US5811814A (en) | 1996-02-12 | 1998-09-22 | Cordis Corporation | Radiation measuring catheter apparatus and method |
| HUP0001261A3 (en) | 1997-04-30 | 2001-11-28 | Univ Washington Seattle | Method of imaging cell death in vivo |
| JP2004510830A (ja) * | 2000-10-11 | 2004-04-08 | ターゲサム・インコーポレーテッド | 標的化された治療用薬剤 |
| US20030152513A1 (en) | 2001-09-06 | 2003-08-14 | Imetrix, Inc. | Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector |
| ATE411819T1 (de) * | 2003-02-17 | 2008-11-15 | Upperton Ltd | Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel |
-
2006
- 2006-09-25 US US11/534,847 patent/US9623129B2/en not_active Expired - Fee Related
- 2006-09-26 WO PCT/US2006/037764 patent/WO2007038641A2/en not_active Ceased
- 2006-09-26 JP JP2008532507A patent/JP2009513568A/ja active Pending
- 2006-09-26 EP EP06815636A patent/EP2341945A2/en not_active Ceased
- 2006-09-26 CA CA2623554A patent/CA2623554C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2341945A4 (en) | 2011-07-13 |
| US9623129B2 (en) | 2017-04-18 |
| CA2623554A1 (en) | 2007-04-05 |
| WO2007038641A2 (en) | 2007-04-05 |
| US20070071676A1 (en) | 2007-03-29 |
| WO2007038641A3 (en) | 2007-10-04 |
| JP2009513568A (ja) | 2009-04-02 |
| EP2341945A2 (en) | 2011-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404343B2 (en) | Humanised anti kallikrein-2 antibody | |
| Kitson et al. | Radionuclide antibody-conjugates, a targeted therapy towards cancer | |
| van de Watering et al. | Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry | |
| DK2771037T3 (en) | Therapeutics and uses thereof | |
| AU2005259258B2 (en) | Radionuclides for medical use | |
| CA2623554C (en) | Methods and therapies for treating inflammatory conditions with exposed collagen | |
| Song et al. | PSMA theragnostics for metastatic castration resistant prostate cancer | |
| Sabbah et al. | In vitro and in vivo comparison of DTPA-and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer | |
| Guidoccio et al. | Novel radiopharmaceuticals for therapy | |
| US9283290B2 (en) | Methods and compositions for treating luminal inflammatory disease | |
| JP4755103B2 (ja) | 動脈硬化性プラークの検出のために使用されるフィブロネクチンのドメインｂ外ドメインのための結合分子 | |
| CA3226530A1 (en) | Netrin-1 detection, companion test and therapy based on radiations | |
| Chopra | 111 In-labeled Ac-Phe-Lys (DTPA)-Tyr-Lys (DTPA)-NH2 (IMP-156)[[111 In]-IMP-156],” | |
| Chen | Radiolabeling and biotinylation of internalizing monoclonal antibody chimeric BR96: Potential use of extracorporeal immunoadsorption with enhanced tumor radioactivity retention of Iodine, Indium and Rhenium | |
| Sgouros | Radionuclides for Therapy | |
| Wahl | Lymphoma | |
| Stoldt et al. | G. Paganelli, M. Chinol | |
| WO2009070786A2 (en) | Peptide and multivalent peptide conjugate for diagnosis and treatment of vascular plaques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220329 |
|
| MKLA | Lapsed |
Effective date: 20200928 |